Review Article

Contribution of Cholesterol and Oxysterols in the Physiopathology of Cataract: Implication for the Development of Pharmacological Treatments

Anne Vejux,1, 2 Mohammad Samadi,3 and Gérard Lizard2

1 Inserm-CIT 808, CHU de Besançon, 25030 Besançon, France
2 Equipe Biochimie Métabolique et Nutritionnelle Centre de Recherche INSERM 866 (Lipides, Nutrition, Cancer), Faculté des Sciences Gabriel, Université de Bourgogne, 6 Boulevard Gabriel, 21000 Dijon, France
3 LCME/Département de Chimie, Université Paul Verlaine-Metz, 57012 Metz, France

Correspondence should be addressed to Gérard Lizard, gerard.lizard@u-bourgogne.fr

Received 23 November 2010; Revised 18 January 2011; Accepted 10 February 2011

Academic Editor: Jie Jin Wang

The development of cataract is associated with some lipid changes in human lens fibers, especially with increased accumulation and redistribution of cholesterol inside these cells. Some direct and indirect lines of evidence, also suggest an involvement of cholesterol oxide derivatives (also named oxysterols) in the development of cataract. Oxysterol formation can result either from nonenzymatic or enzymatic processes, and some oxysterols can induce a wide range of cytotoxic effects (overproduction of reactive oxygen species (ROS); phospholipidosis) which might contribute to the initiation and progression of cataract. Thus, the conception of molecules capable of regulating cholesterol homeostasis and oxysterol levels in human lens fibers can have some interests and constitute an alternative to surgery at least at early stages of the disease.

1. Cholesterol Oxidation Products (Oxysterols): Definition and Biosynthesis

Oxysterols are 27-carbon-atom cholesterol oxidation products [1]. They can be produced endogenously by enzymatic reactions or by autoxidation. They also can be provided by food [1]. The enzymatic pathways can form both B-ring and side-chain hydroxylated oxysterols depending on the enzyme and the tissue, while the nonenzymatic pathways form mainly B-ring oxysterols.

By the enzymatic pathway, oxysterols can be generated by a wide number of CYP450 enzymes [2]. Some of them are tissue specific. Thus, CYP46A1 (or 24-hydroxylase) leading to the formation of 24-hydroxycholesterol has been identified in the brain [3] and retina [4]. CYP7A1 which catalyzes the formation of 7α-hydroxycholesterol is present in the liver, and involved in bile acid synthesis [5]. At the opposite, some other CYP450 enzymes are widely expressed. Thus, CYP27A1 (or 27-hydroxylase), which catalyzes the addition of a hydroxyl group on cholesterol to produce 27-hydroxycholesterol, is found in most tissues [6]. Cholesterol 25-hydroxylase, leading to the formation of 25-hydroxycholesterol, is a nonheme iron protein enzyme, also present in many tissues [7].

Oxysterols can also be generated within tissues by nonenzymatic oxidative reactions involving different chemical and/or physical agents: reactive oxygen species (ROS), ozone, ultra violet light, metal ions, ferritin, and/or other iron-carrying proteins, and so forth. These autoxidation processes generate 7α- or 7β-hydroperoxide, 7α- or 7β-hydroxycholesterol, and 7-ketocholesterol, 5α, 6α- or 5β, 6β-epoxycholesterol, as well as cholesterol 3β, 5α, 6β triol or cholesterol 3β, 5α, 6α triol depending on pH conditions (Figure 1) [8–10]. In certain conditions, 7-ketocholesterol can be produced from 7β-hydroxycholesterol and vice versa by a converting enzyme [11].
Currently, in humans, the involvement of oxysterols is suspected in the Smith-Lemli-Opitz syndrome [12, 13], and in numerous eye diseases (age-related macular degeneration, diabetic retinopathy,) [14, 15], and could contribute to the development of cataract [16].

**2. Cholesterol and Oxysterols: Which Roles in Cataract?**

Cataract, which is a term referring to the clouding of the eye’s natural lens, is the dominant cause of blindness worldwide [17]. This disease develops as early as the fourth or fifth decade of life in the crystalline lens of the eye or in its envelope, varying in degree from slight to complete opacity and obstructing the passage of light. Symptoms include blurred vision, glare, halos, dull colors, and cloudy vision. Whereas the most important factor in cataract formation is increasing age, it is well admitted that cataract formation is a multifactorial disease associated with additional factors such as smoking, diabetes, and excessive exposure to sunlight which are known to activate oxidative stress [17]. Currently, surgical intervention is the most frequent and efficient treatment to restore vision in patients with cataract. However, the cure for cataract surgery is not equally available to all, and the surgery which is available does not produce equal outcomes. In addition, readily available surgical services capable of delivering good vision rehabilitation are not always acceptable and accessible to all in need. Therefore, a better knowledge of the physiopathology of cataract is required in order to attempt to develop, if not curative, at least preventive treatments.

The concept suggesting a possible involvement of lipids in human cataract is based on the description of lipoidal material in the crystalline lens reported by Berzelius in 1825 [18]. Since this early discovery, some investigators have studied the lenticular lipids leading to lens opacity. In 1965, by using one and two dimensional thin layer chromatography, Feldman GL and Felman LS show higher amounts of cholesterol, cephalins, lecithin, and sphingomyelin in cataractous human lens when compared to normal lens, and they also show that cholesterol is constitutively present in large amount in normal lens [16]. Therefore, cholesterol representing approximately 40% of the total lipids of human lens fibers [19], intrinsic or extrinsic factors modifying its level and/or repartition, may alter optical lens properties. Some cholesterols can be present as crystals, which have been found in plasma membranes isolated from the lens [20, 21], and which may play functional roles in normal and pathological lens [22]. The formation of these crystals is related to the lipid composition of the lens, and seems to depend on the presence of sphingomyelin and dihydrosphingomyelin [23]. The part taken by cholesterol in the development of cataract is also supported by observations performed in various pathologies associated with defects in cholesterol metabolism. Thus, patients with Smith-Lemli-Opitz syndrome, mevalonic aciduria, or cerebrotendinous xanthomatosis characterized by mutations in enzymes of cholesterol metabolism (7-dehydrocholesterol reductase, mevalonate kinase, and CYP27A1, resp.) often develop cataract [24]. In addition, established models of rodent cataracts are based on treatment with inhibitors of cholesterol biosynthesis, and some statins can produce...
cataracts in dogs [24]. Moreover, with regards to oxidative
damages, as the lipid lens composition is devoid of oxidizable
polyunsaturated fatty acids, and as there is a high content of
dihydrospingomyelin that is less prone to oxidation, this
particular lipid composition favors cholesterol autoxidation.
Thus, as human lens membrane contains the highest
cholesterol levels of any known biological membranes, and
as human lens is continuously in a strong phototoxicative
environment, a chronic exposure to UV light, and ozone can
lead to the formation of some cholesterol oxide derivatives
(also named oxysterols) [25–30] which might contribute to
disrupt cholesterol repartition and homeostasis in human
lens fibers. Noteworthy, on human cataracts obtained by rou-
tine extracellular surgery, some oxysterols characterized by
gas chromatography were identified (7β-hydroxycholesterol,
7-ketocolesterol, 5α, 6α-epoxycholestanol, 20α-hydroxy-
cholesterol, and 25-hydroxycholesterol) whereas clear lens
contained no detectable amounts of cholesterol oxides [31].
These data favor the hypothesis that oxysterols may be
involved in cataract development. Moreover, as 7-keto-
cholesterol has been described to modify Na/K ATPase
activity [32], and intracellular lipid homeostasia [33], this
oxysterol might constitute an important risk factor in the
physiopathology of cataract. Indeed, it has been described
that Na/K ATPase activity is fundamental to the maintenance
of ionic concentration gradients and transparency of the
lens [34], and that unusual lipid composition modify lens
membrane fluidity [35].

Some indirect arguments also support potential involve-
ment of cholesterol and oxidative stress, mainly able to
favor the formation of oxysterols oxidized at C7 [11], in the
development of cataract: decrease paraoxanase 1 activity and
higher levels of oxidized LDL in diabetic and senile subjects
suffering from cataract [36], low level of HDL cholesterol
and high LDL: HDL ratios in dyslipidaemic subjects with
lenticular opacities [37], low serum concentrations of the
antioxidant vitamins alpha tocopherol and beta carotene
in end age senile cataract [38], and significant decrease
of glutathione reductase activity in patients with cortical
cataract [39]. In addition, as some oxysterols are known
to interact with cellular membranes [40–42] and to induce
changes in cholesterol and phospholipids content [43, 44],
they could also modify the distribution of cholesterol in
human lens fibers to contribute to lens opacity [45–49].

3. Alternative Pharmacological Treatments to
Cataract Surgery

Phacoemulsification developed by Kelman in 1967 [50]
is nowadays the preferred technique in most types of
cataract. It results in less postoperative inflammation and
astigmatism, more rapid visual rehabilitation and, with
modern foldable lenses, a lower incidence of capsulotomy
than with the outdated extracapsular surgery [50]. However,
whereas surgical treatment with intraocular lens implan-
tation remains the only proven treatment, it is associated
with significant cost and is not readily available especially in
the developing countries where the prevalence of cataract is
the highest [51]. Therefore, nonsurgical preventive actions
have been proposed to interact at the level of altered
lens metabolism: Aldose-Reductase inhibitors (to block
the metabolic pathways of glucose responsible for dia-
abetic vascular dysfunction); nonsteroidal anti-inflammatory
drugs (as prophylactic anticataract agents); agents enhancing
reduced glutathione levels; Vitamins (Vitamin C plays an
and as a UV filter); minerals (zinc, copper, selenium);
antioxidants (carotenoids, curcumin, stobadine, etc.), and
herbal drugs [52, 53]. However, the long-term efficiency of
these alternative pharmacological treatments of cataract is
far to be established. Therefore, within this framework, the
research for molecules that can act at the level of chole-
sterol or oxysterols metabolism and/or synthesis could be
promising.

Currently, due to a better knowledge of the cholesterol-
metabolic pathway and of its regulation through various
tightly regulated cellular systems involving various nuclear
receptors [54], some molecules capable of regulating choles-
terol levels have been identified and are available [55–57].
It can therefore be envisaged to modulate cholesterol levels
in various cells, including lens fiber cells. On the other
hand, due to the improvement of biochemical methods of
analyses, especially mass-chromatography, some oxysterols
can be measured and identified in various biological samples
which usually contain a 10^3 fold excess of cholesterol [58–
60]. As some oxysterols with specific structural motifs have
been shown to inhibit cholesterol synthesis by interacting
with proteins involved in regulation of transcription of
genes encoding enzymes of the cholesterol synthesis pathway
[61] and to be ligands of the liver X receptors (LXRs)
[62, 63] acting as regulators of the expression of genes
important for lipid homeostasis, a better knowledge of
oxysterols-associated metabolic profiles has some interests in
various pathologies resulting from lipid disorders, and could
therefore have some pharmacological applications, especially
for the treatment of cataract.

Thus, at the opposite of micronutrient and vitamin sup-
plementation which can contribute more or less efficiently
to prevent the development of cataract, it is tempting to
speculate that the development of drugs capable of acting
on well-defined targets of cholesterol metabolism, and on
enzymatic and/or nonenzymatic formation of oxysterols
might be efficient to preserve cholesterol homeostasia and
distribution in human lens fibers, and to control oxysterol
formation and activities. Such drugs could therefore consti-
tute an alternative to surgery at least at the early stage of the
disease.

4. Conclusion

Thus, based on numerous data and comparatively to other
degenerative diseases [64, 65], it is tempting to speculate
that cholesterol and some oxysterols probably play impor-
tant roles in the physiopathology of cataract. Therefore,
molecules allowing to control cholesterol and oxysterol levels
in the lens might have some interests to prevent cataract and
constitute an alternative treatment to surgery, at least at early
stages of the disease.
Acknowledgments

This work was supported by grants from the INSERM, the Université de Bourgogne, and the Conseil Régional de Bourgogne. The ENOR (European Network on Oxysterol Research; http://www.oxysterolsnet.org/) is acknowledged for helpful discussions on oxysterol analysis and functions (LipidomicNet and ENOR joint Workshop, Munich, Germany, 19–20 November, 2010).

References

[1] A. Otegui-Arrazola, M. Menéndez-Carreño, D. Ansorena, and I. Astiasarán, “Oxysterols: a world to explore,” Food and Chemical Toxicology, vol. 48, no. 12, pp. 3289–3303, 2010.

[2] D. W. Russell, “Oxysterol biosynthetic enzymes,” Biochimica et Biophysica Acta, vol. 1529, no. 1–3, pp. 126–135, 2000.

[3] I. Björkhem, D. Lütjohann, U. Diczfalusy, L. Stährle, G. Ahlborg, and J. Wahren, “Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this in the circulation,” Journal of Lipid Research, vol. 39, no. 8, pp. 1594–1600, 1998.

[4] L. Bretillon, U. Diczfalusy, I. Björkhem et al., “Cholesterol-24S-hydroxy- (CYP46A1) is specifically expressed in neurons of the neural retina,” Current Eye Research, vol. 32, no. 4, pp. 361–366, 2007.

[5] M. I. Monte, J. J. G. Marin, A. Antelo, and J. Vazquez-Tato, “Bile acids: chemistry, physiology, and pathophysiology,” World Journal of Gastroenterology, vol. 15, no. 7, pp. 804–816, 2009.

[6] I. A. Pikuleva, “Cholesterol-metabolizing cytochromes P450,” Drug Metabolism and Disposition, vol. 34, no. 4, pp. 513–520, 2006.

[7] N. B. Javitt, “Cholesterol, hydroxysteroids, and bile acids,” Biochemical and Biophysical Research Communications, vol. 292, no. 5, pp. 1147–1153, 2002.

[8] L. L. Smith, Cholesterol Autoxidation, Plenum Press, New York, NY, USA, 1981.

[9] W. Korytowski, G. I. Bachowski, and A. W. Girotti, “Photoperoxidation of cholesterol in homogeneous solution, isolated membranes, and cells: comparison of the 5α- and 6β-hydroperoxides as indicators of singlet oxygen intermediacy,” Photochemistry and Photobiology, vol. 56, no. 1, pp. 1–8, 1992.

[10] A. W. Girotti and W. Korytowski, “Cholesterol as a singlet oxygen detector in biological systems,” Methods in Enzymology, vol. 319, pp. 85–100, 2000.

[11] A. J. Brown and W. Jessup, “Oxysterols: sources, cellular storage and metabolism, and new insights into their roles in cholesterol homeostasis,” Molecular Aspects of Medicine, vol. 30, no. 3, pp. 111–122, 2009.

[12] N. B. Javitt, “Oxysterols: functional significance in fetal development and the maintenance of normal retinal function,” Current Opinion in Lipidology, vol. 18, no. 3, pp. 283–288, 2007.

[13] Z. Korade, L. Xu, R. Shelton, and N. A. Porter, “Biological activities of 7-dehydrocholesterol-derived oxysterols: implications for Smith-Lemli-Opitz syndrome,” Journal of Lipid Research, vol. 51, no. 11, pp. 3259–3269, 2010.

[14] C. A. Curcio, C. L. Millican, T. Bailey, and H. S. Kruth, “Accumulation of cholesterol with age in human Bruch’s membrane,” Investigative Ophthalmology and Visual Science, vol. 42, no. 1, pp. 265–274, 2001.

[15] L. Malvitte, T. Montange, C. Joffre et al., “Analogies between atherosclerosis and age-related maculopathy: expected roles of oxysterols,” Journal Francais d’Ophtalmologie, vol. 29, no. 5, pp. 570–578, 2006.

[16] G. L. Feldman and L. S. Feldman, “New concepts of human lenticular lipids and their possible role in cataracts,” Investigative Ophthalmology, vol. 4, pp. 162–166, 1965.

[17] G. F. J. M. Vrensen, “Early cortical lens opacities: a short overview,” Acta Ophthalmologica, vol. 87, no. 6, pp. 602–610, 2009.

[18] J. J. Berzelius, Lehrbuch der Chemie, Arnold, Dresden, Germany, 1825–1831.

[19] S. Zigmans, T. Paxhia, G. Marinetti, and S. Girsch, “Lipids of human lens fiber cell membranes,” Current Eye Research, vol. 3, no. 7, pp. 887–896, 1984.

[20] R. F. Jacob, R. J. Cenedella, and W. P. Mason, “Direct evidence for immiscible cholesterol domains in human ocular lens fiber cell plasma membranes,” Journal of Biological Chemistry, vol. 274, no. 44, pp. 31613–31618, 1999.

[21] R. F. Jacob, R. J. Cenedella, and R. P. Mason, “Evidence for distinct cholesterol domains in fiber cell membranes from cataractous human lenses,” Journal of Biological Chemistry, vol. 276, no. 17, pp. 13573–13578, 2001.

[22] R. P. Mason, T. N. Tumenko, and R. F. Jacob, “Direct evidence for cholesterol crystalline domains in biological membranes: role in human pathobiology,” Biochimica et Biophysica Acta, vol. 1610, no. 2, pp. 198–207, 2003.

[23] R. M. Epand, “Cholesterol in bilayers of sphingomyelin or dihydrosphingomyelin at concentrations found in ocular lens membranes,” Biophysical Journal, vol. 84, no. 5, pp. 3102–3110, 2003.

[24] R. J. Cenedella, “Cholesterol and cataracts,” Survey of Ophthalmology, vol. 40, no. 4, pp. 320–337, 1996.

[25] P. Wentworth Jr., J. Nieva, C. Takeuchi et al., “Evidence for ozone formation in human atherosclerotic arteries,” Science, vol. 302, no. 5647, pp. 1053–1056, 2003.

[26] A. Vejux and G. Lizard, “Cytotoxic effects of oxysterols associated with human diseases: induction of cell death (apoptosis and/or oncosis), oxidative and inflammatory activities, and phospholipidosis,” Molecular Aspects of Medicine, vol. 30, no. 3, pp. 153–170, 2009.

[27] G. Brian and H. Taylor, “Cataract blindness—challenges for the 21st century,” Bulletin of the World Health Organization, vol. 79, no. 3, pp. 249–256, 2001.

[28] L. L. Smith, “Cholesterol autoxidation 1981–1986,” Chemistry and Physics of Lipids, vol. 44, no. 2–4, pp. 87–125, 1987.

[29] M. K. Pulfer, C. Taube, E. Gelfand, and R. C. Murphy, “Ozone exposure in vivo and formation of biologically active oxysterols in the lung,” Journal of Pharmacology and Experimental Therapeutics, vol. 312, no. 1, pp. 256–264, 2005.

[30] M. A. Dreyfus, M. P. Tolocka, S. M. Dodds, J. Dykins, and M. V. Johnston, “Cholesterol ozonolysis: kinetics, mechanism and oligomer products,” Journal of Physical Chemistry A, vol. 109, no. 28, pp. 6242–6248, 2005.

[31] H. Girão, M. C. Mota, J. Ramalho, and P. Pereira, “Cholesterol oxides accumulate in human cataracts,” Experimental Eye Research, vol. 66, no. 5, pp. 645–652, 1998.

[32] M. J. Duran, S. V. Pierre, P. Lesnik et al., “7-ketocholesterol inhibits Na,K-ATPase activity by decreasing expression of its α1-subunit and membrane fluidity in human endothelial cells,” Cell and Molecular Biology, vol. 56, supplement, pp. OL1434–OL1441, 2010.
[33] A. Vejux, E. Kahn, D. Dumas et al., “7-ketocholesterol favors lipid accumulation and colocalizes with Nile Red positive cytoplasmic structures formed during 7-ketocholesterol-induced apoptosis: analysis by flow cytometry, FRET biphoton spectral imaging microscopy, and subcellular fractionation,” Cytometry Part A, vol. 64, no. 2, pp. 87–100, 2005.

[34] D. Lichtstein, M. H. McGowan, P. Russell, and D. A. Carper, “Digitalis and digitalislike compounds down-regulate gene expression of the intracellular signaling protein 14-3-3 in rat lens,” Hypertension Research, vol. 23, supplement, pp. S51–S53, 2000.

[35] M. H. McGowan, P. Russell, D. A. Carper, and D. Lichtstein, “Na+, K+-ATPase inhibitors down-regulate gene expression of the intracellular signaling protein 14-3-3 in rat lens,” Journal of Pharmacology and Experimental Therapeutics, vol. 289, no. 3, pp. 1559–1563, 1999.

[36] Z. Hashim and S. Zarina, “Assessment of paraoxonase activity and lipid peroxidation levels in diabetic and senile subjects suffering from cataract,” Clinical Biochemistry, vol. 40, no. 9-10, pp. 705–709, 2007.

[37] D. Meyer, D. Parkin, F. J. Maritz, and P. H. Liebenberg, “Abnormal serum lipoprotein levels as a risk factor for the development of human lenticular opacities,” Cardiovascular Journal of South Africa, vol. 14, no. 2, pp. 60–64, 2003.

[38] P. Knekt, M. Heliovaara, A. Rissanen, A. Aromaa, and R. K. Aaran, “Serum antioxidant vitamins and risk of cataract,” British Medical Journal, vol. 305, no. 6866, pp. 1392–1394, 1992.

[39] C. Ohloff, L. Korte, and I. Doffin, “Studies of lens enzyme activities in relation to cataract type and plasma constituents,” Ophthalmic Research, vol. 15, no. 3, pp. 136–139, 1983.

[40] M. C. Royer, S. Lemaine-Ewing, C. Desrumaux et al., “7-ketocholesterol incorporation into sphingolipid/cholesterol-enriched (lipid raft) domains is impaired by vitamin E. A specific role for α-tocopherol with consequences on cell death,” Journal of Biological Chemistry, vol. 284, no. 23, pp. 15826–15834, 2009.

[41] J. Wang, . Megha, and E. London, “Relationship between sterol/sterol structure and participation in ordered lipid domains (lipid rafts): implications for lipid raft structure and function,” Biochemistry, vol. 43, no. 4, pp. 1010–1018, 2004.

[42] E. Mintzer, G. Charles, and S. Gordon, “Interaction of two oxysterols, 7-ketocholesterol and 25-hydroxycholesterol, with phosphatidylcholine and sphingomyelin in model membranes,” Chemistry and Physics of Lipids, vol. 163, no. 6, pp. 586–593, 2010.

[43] E. Kahn, A. Vejux, and D. Dumas, “FRET multiphoton spectral imaging microscopy of 7-ketocholesterol and Nile Red in U937 monocyte cells loaded with 7-ketocholesterol,” Analytical Quantitative Cytology and Histology, vol. 26, no. 6, pp. 304–313, 2004.

[44] A. Vejux, L. Malvitte, and G. Lizard, “Side effects of oxysterols: cytotoxicity, oxidation, inflammation, and phospholipidosis,” Brazilian Journal of Medical and Biological Research, vol. 41, no. 7, pp. 545–556, 2008.

[45] A. Vejux, S. Guyot, T. Montange, J. M. Riedinger, E. Kahn, and G. Lizard, “Phospholipidosis and down-regulation of the PI3-K/PDK-1/Akt signalling pathway are vitamin E inhibitable events associated with 7-ketocholesterol-induced apoptosis,” Journal of Nutritional Biochemistry, vol. 20, no. 1, pp. 45–61, 2009.

[46] D. Borchman, N. A. Delamere, L. A. McCauley, and C. A. Paterson, “Studies on the distribution of cholesterol, phospholipid, and protein in the human and bovine lens,” Lens and Eye Toxicity Research, vol. 6, no. 4, pp. 703–724, 1989.

[47] J. J. Duindam, G. F. J. M. Vreens, C. Otto, and J. Greve, “Cholesterol, phospholipid, and protein changes in focal opacities in the human eye lens,” Investigative Ophthalmology and Visual Science, vol. 39, no. 1, pp. 94–103, 1998.

[48] D. Borchman and M. C. Yappert, “Lipids and the ocular lens,” Journal of Lipid Research, vol. 51, no. 9, pp. 2473–2488, 2010.

[49] M. Rujoj, J. Jin, D. Borchman, D. Tang, and M. C. Yappert, “Isolation and lipid characterization of cholesterol-enriched fractions in cortical and nuclear human lens fibers,” Investigative Ophthalmology and Visual Science, vol. 44, no. 4, pp. 1634–1642, 2003.

[50] C. D. Kelman, “Phaco-emulsification and aspiration. A new technique of cataract removal. A preliminary report,” American Journal of Ophthalmology, vol. 64, no. 1, pp. 23–35, 1967.

[51] T. Y. Toh, J. Morton, J. Coxon, and M. J. Elder, “Medical treatment of cataract,” Clinical and Experimental Ophthalmology, vol. 35, no. 7, pp. 664–671, 2007.

[52] A. Pollreisz and U. Schmidt-Erfurth, “Diabetic cataract—pathogenesis, epidemiology and treatment,” Journal of Ophthalmology, vol. 2010, Article ID 608751, 8 pages, 2010.

[53] S. K. Gupta, V. K. Selvan, S. S. Agrawal, and R. Saxena, “Advances in pharmacological strategies for the prevention of cataract development,” Indian Journal of Ophthalmology, vol. 57, no. 3, pp. 175–183, 2009.

[54] F. R. Maxfield and G. van Meen, “Cholesterol, the central lipid of mammalian cells,” Current Opinion in Cell Biology, vol. 22, pp. 422–429, 2010.

[55] S. Sanyal, J. T. Kuvin, and R. H. Karas, “Niacin and laropiprant,” Drugs of Today, vol. 46, no. 6, pp. 371–378, 2010.

[56] S. Katragadda, F. Rai, and R. Arora, “Dual inhibition, newer paradigms for cholesterol lowering,” American Journal of Therapeutics, vol. 17, no. 4, pp. e88–e99, 2010.

[57] A. Kamal-Eldin and A. Moazzami, “Plant sterols and stanols as cholesterol-lowering ingredients in functional foods,” Recent Patents on Food, Nutrition & Agriculture, vol. 1, no. 1, pp. 1–14, 2009.

[58] W. J. Griffiths and Y. Wang, “Analysis of neurosteroids by GC-MS and LC-MS/MS,” Journal of Chromatography B, vol. 877, no. 26, pp. 2778–2805, 2009.

[59] W. J. Griffiths and J. Sjövall, “Analytical strategies for characterization of bile acid and oxysterol metabolomes,” Biochemical and Biophysical Research Communications, vol. 396, no. 1, pp. 80–84, 2010.

[60] D. Lütjohann, M. Marinova, B. Schneider et al., “4β-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo—effects of itraconazole in man,” International Journal of Clinical Pharmacology and Therapeutics, vol. 47, no. 12, pp. 709–715, 2009.

[61] M. S. Brown and J. L. Goldstein, “Cholesterol feedback: from Schoenheimer’s bottle to Scap’s MELADL,” Journal of Lipid Research, vol. 50, supplement, pp. S15–S27, 2009.

[62] J. Beltowski, “Liver X receptors (LXR) as therapeutic targets in dyslipidemia,” Cardiovascular Therapeutics, vol. 26, no. 4, pp. 297–316, 2008.

[63] H. Ratni and M. B. Wright, “Recent progress in liver X receptor-selective modulators,” Current Opinion in Drug Discovery and Development, vol. 13, no. 4, pp. 403–413, 2010.
[64] I. R. Rodríguez and I. M. Larrayoz, “Cholesterol oxidation in the retina: implications of 7KCh formation in chronic inflammation and age-related macular degeneration,” *Journal of Lipid Research*, vol. 51, no. 10, pp. 2847–2862, 2010.

[65] S. Lordan, J. J. Mackrill, and N. M. O’Brien, “Oxysterols and mechanisms of apoptotic signaling: implications in the pathology of degenerative diseases,” *Journal of Nutritional Biochemistry*, vol. 20, no. 5, pp. 321–336, 2009.